Drugdu.com expert's response:

Under the EU MDR Regulation, the core of efficiently carrying out clinical evaluation is to avoid repeated rectification in the later stage and greatly shorten the compliance cycle through advance planning, process standardization and pre-risk control. Below are the directly implementable efficient methods:

1. Build a Standardized Clinical Evaluation Plan (CEP) in Advance

‌Clarify core elements‌: Directly anchor the general safety and performance requirements supported by clinical data, the precise target patient population of the product, and quantifiable clinical benefit indicators in the plan to avoid repeated supplementation in subsequent stages.

‌Align compliance boundaries in advance‌: Proactively align with the requirements of MDR Annex XIV and MDCG 2021-6 guideline, so as to avoid common problems caused by missing plan elements from the very beginning.

‌Reserve a gap prediction session‌: Preset the execution nodes for literature retrieval and data assessment in advance, to identify potential clinical evidence gaps ahead of schedule.

2. Consolidate the Evidence Base Rapidly via Structured Literature Retrieval

‌Conduct Systematic Literature Review (SLR)‌: Establish a standardized retrieval template, specify the retrieval databases, keywords, inclusion/exclusion criteria, and keep the fully traceable complete retrieval path documentation throughout the process.

‌Complete equivalence demonstration efficiently‌: Build an equivalent device comparison template in advance, fully compare the manufacturer information, material parameters, CE certificates and clinical data of equivalent products, to meet the MDR equivalence demonstration requirements at one time and avoid repeated evidence supplementation.

‌Locate evidence gaps quickly‌: Directly identify the missing clinical data through initial literature screening, eliminating the need for rework and supplementation in the later stage.

3. Reduce Duplicate Work Through Phased Data Assessment

‌Evaluate existing data in layers‌: First conduct hierarchical assessment on existing clinical data, Post-Market Surveillance (PMS) data, and public literature of similar products, and prioritize the reuse of evidence with verified compliance.

‌Supplement new data in a targeted manner‌: Only design streamlined clinical studies as needed for the clearly identified evidence gaps, without carrying out redundant clinical trials.

‌Cover verification for all populations‌: Establish an "applicable population evidence sheet" in advance, check the evidence coverage of special populations such as the elderly, children and pregnant women one by one. If no corresponding data is available, set usage restrictions or risk mitigation measures in advance.

4. Synchronize and Connect Compliance Actions Across the Full Life Cycle

‌Output the Clinical Evaluation Report (CER) simultaneously‌: Directly integrate all assessment conclusions, evidence chains, and benefit-risk judgments into the report, to ensure that all elements of the report fully meet MDR requirements without multiple iterations and modifications.

‌Plan PMCF activities in advance‌: Develop the Post-Market Clinical Follow-up (PMCF) scheme synchronously at the clinical evaluation stage, and take PMCF data as a continuous supplementary source for clinical evaluation, avoiding building the system separately in subsequent stages.

‌Implement cross-team collaborative control‌: The registration compliance team and the clinical team jointly maintain an "adverse reaction library", establish a quantitative risk assessment process, and complete the compliance judgment of residual risks and adverse events at one time.